Arron Mungul
About Arron Mungul
Arron Mungul is the Director of Medical Capabilities (International Markets) at Bristol-Myers Squibb and a member of the Medical Affairs Professional Society in London, UK. He has extensive experience in oncology, medical communications, and launch readiness for immuno-oncology products.
Current Roles and Responsibilities
Arron Mungul is currently serving as the Director of Medical Capabilities (International Markets) at Bristol-Myers Squibb in London, United Kingdom. Concurrently, he is a Member of the Focus Area Working Group for Strategy & Launch Excellence at the Medical Affairs Professional Society (MAPS) in London, England.
Career at Bristol-Myers Squibb
Arron Mungul previously worked at Bristol-Myers Squibb as the EMAC-Intercon Markets Interface Lead Immuno-Oncology (Worldwide Medical) from 2015 to 2018. In this role, he was instrumental in ensuring launch readiness and optimization for immuno-oncology products across European, Australian, Canadian, and Emerging Markets.
Previous Work Experience
Before joining Bristol-Myers Squibb, Arron Mungul held multiple roles in leading pharmaceutical companies. He served as a Senior Scientific Director (Global Oncology) at Novartis in 2015, and prior to that, he was a Senior Scientific Director and Senior Scientific Advisor in Global Oncology Medical Affairs at GlaxoSmithKline from 2011 to 2015. He also worked as a Medical Communications Advisor (Oncology) from 2009 to 2011.
Education and Academic Background
Arron Mungul earned his PhD from Cancer Research UK, where he studied from 1998 to 2002. He also holds a BSc (Hons) degree from Imperial College London, which he completed from 1994 to 1998. His education has provided a strong foundation for his extensive career in medical affairs and oncology.
Scientific and Management Expertise
Throughout his career, Arron Mungul has developed extensive expertise in leading the development of Medical Affairs Plans, competitive intelligence, and congress activities. He has line management experience, having mentored several individuals in the field of medical affairs. He played a key role in the global launch of Votrient® (pazopanib) and was responsible for scientific communications to support launch plans and post-marketing activities.